Health Economics & Outcomes Research Experts
ProBridge is a global consulting company that helps pharmaceutical and biotechnology companies demonstrate the value of their therapies — across health economics and outcomes research, real-world data and evidence, patient-reported outcomes, survey research, and HTA engagement, from early development through launch and beyond.
Bridging Health Economics Expertise, Real-World Evidence & AI for Better Health Outcomes
With 25+ years in health economics, outcomes research, and real-world evidence, ProBridge builds the evidence that proves your product’s value.
That experience is hands-on. Our leaders have built and run real-world evidence groups inside some of the world’s largest pharmaceutical companies, held senior roles in value generation, market access, and global pricing and access, and carried pricing and reimbursement submissions through to approval in multiple countries — supported by a network of former HTA reviewers and academic collaborators.
Health Economics & Outcomes Research
Economic models, cost-effectiveness and budget-impact analyses, burden-of-illness studies, and value dossiers that make the health-economic case for your therapy to payers and HTA bodies — backed by an extensive peer-reviewed publication record in outcomes research.
Real-World Data & Evidence
End-to-end real-world evidence — data-source identification, feasibility, study design, protocol development, and analysis. Led by a PhD econometrician who built RWE functions inside some of the world’s largest pharmaceutical companies and has helped shape how external and synthetic control arms are evaluated.
Value Creation for Products in Development
For assets still in development: target value propositions, integrated evidence-generation planning, and payer and HTA readiness. Shaped by senior leaders from market access and global pricing and access, with experience in payer strategy, strategic contracting for high-cost oncology therapies, and multi-country reimbursement submissions.
“We brought ProBridge in on a real-world evidence study that was heading for trouble. They rebuilt the design, tightened the analysis, and the external control arm held up under regulatory scrutiny — it changed the outcome.”
“The value story we took into HTA review was materially stronger because of ProBridge — they anticipated the committee’s questions before we did.”
“They operate like senior colleagues, not vendors. They’ve sat on the payer and HTA side, and it shows in the evidence they build.”
Evidence gaps surface at the worst possible time — in an HTA review, a payer negotiation, or at launch — and they are slow and costly to close. From early asset planning through launch and beyond, we build and run the evidence strategy that demonstrates your product’s value, pairing deep HEOR and real-world research expertise with AI tools that make the work faster and sharper.
Our Capabilities & Services
Patient-Reported Outcomes & Survey Research
PRO strategy and instrument selection, psychometric validity and reliability analysis, population-based norm generation, population-level data collection, and primary survey research — assembled into PRO dossiers that bring the patient and stakeholder voice into your evidence base.
AI Tools & Solutions
Custom AI applications built into your research workflows — including our Product Intelligence Vault, a structured view of an asset’s evidence and value story. We accelerate literature and data-source review, structure evidence, and automate repetitive analysis so your experts focus on interpretation and strategy.
Staffing Solutions
Experienced health economics, real-world evidence, biostatistics, and scientific writing professionals embedded with your team — for a defined project, a resourcing gap, or an ongoing function.
HTA Engagement & Advisory
Preparation and support for interactions with health technology assessment bodies worldwide — including NICE (UK), HAS (France), G-BA and IQWiG (Germany), CADTH (Canada), PBAC (Australia), HIRA (South Korea), and the EU Joint Clinical Assessment — spanning evidence-requirement gap analysis, submission strategy, mock reviews, and response planning. We also convene former HTA reviewers and academic experts to pressure-test your value story before it counts.
Contact Us
Tell us where your asset is in development and the evidence or access question you’re facing — we’ll come back with how we’d approach it.
